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Abstract
Potential benefits of any therapy must be weighed against potential risks. Among patients with non-del(5q)
lower-risk myelodysplastic syndromes, the rate of clinical benefit was significantly higher with lenalidomide
versus placebo. Despite the occurrence of hematologic adverse events, the benefit-risk profile favored
lenalidomide over placebo. Managing hematologic adverse events by dose reductions can help patients remain
on treatment and achieve clinical benefit.
Background: In the phase III MDS-005 study of patients with lower-risk, non-del(5q) myelodysplastic syndromes,
lenalidomide was associated with a higher rate of  8 weeks red blood cell transfusion independence (RBC-TI)
compared with placebo, but also with a higher risk of hematologic adverse events (AEs). Patients and Methods: This
analysis evaluated the ratio of clinical benefit-risk in patients treated with lenalidomide or placebo, and assessed the
effect of lenalidomide dose reductions on response. Clinical benefit was a composite endpoint defined as RBC-TI,
transfusion reduction  4 units packed red blood cells, hemoglobin increase  1.5 g/dL, or cytogenetic response.
Results: The rate of clinical benefit was higher with lenalidomide than with placebo (31.9% vs. 3.8%). The ratio of
response (RBC-TI and clinical benefit) to risk (hematologic AEs) favored lenalidomide over placebo. Patients who
underwent  1 lenalidomide dose reduction had a longer duration of treatment, received a higher cumulative dose,
and were more likely to experience clinical benefit versus patients without dose reductions. Conclusion: Despite the
occurrence of hematologic AEs, the overall benefit-risk profile supported lenalidomide treatment. Appropriate
management of hematologic AEs by dose reductions may help patients with myelodysplastic syndromes to remain on
treatment and achieve clinical benefit.
Clinical Lymphoma, Myeloma & Leukemia, Vol. 19, No. 4, 213-9 ª 2018 Published by Elsevier Inc.
Keywords: Adverse events, Benefit-risk ratio, Dose reduction, Response, Treatment exposureIntroduction
Supportive care remains the standard treatment approach for
anemia associated with lower-risk myelodysplastic syndromes
(MDS).1 Erythropoiesis-stimulating agents (ESAs) are often first-line
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Clinical Benefit-Risk Profile of Lenalidomide in Lower-Risk Non-del(5q) MDSResponse to ESAs can be predicted based on baseline erythropoietin
(EPO) level and transfusion history.5 In the event of ESA failure, few
treatment options are available that can provide prolonged reductions
in red blood cell (RBC) transfusion requirement.
The efficacy and safety of lenalidomide was evaluated in RBC
transfusion dependent (RBC-TD) patients with International
Prognostic Scoring System (IPSS) Low- or Intermediate (Int)-1-risk
non-del(5q) MDS who were ineligible for or refractory to ESAs in
the phase III MDS-005 study.6 In this study, a statistically signif-
icant and clinically relevant proportion of lenalidomide-treated
patients achieved RBC transfusion independence (RBC-TI)
lasting  8 weeks compared with placebo (26.9% vs. 2.5%;
P < .001). Achievement of RBC-TI is a particularly meaningful
endpoint for patients with RBC-TD anemia, as prolonged trans-
fusion dependence is associated with transfusion-related comor-
bidities7 and considerably impaired health-related quality of life
(HRQoL).8 In the MDS-005 study, achievement of RBC-TI  8
weeks was associated with significant improvements in HRQoL
(P < .01). Other important measures of treatment response, such as
reduction in transfusion burden or increase in hemoglobin (Hb),
also represent clinically meaningful improvements in anemia and
anemia-related symptoms for patients with RBC-TD MDS.
When assessing clinical benefit, the most prominent adverse drug
reactions should also be taken into account in order to define the
most favorable balance between benefit and risk. The most common
treatment-emergent adverse events (TEAEs) reported in the MDS-
005 study were hematologic, consistent with the known TEAE
profile of lenalidomide in MDS.9-12 Adverse events (AEs) can
negatively impact HRQoL and lead to drug discontinuation.
Appropriate management of TEAEs, including dose reductions, is
therefore essential for preventing early discontinuation and main-
taining patients on therapy.
This analysis of data from the MDS-005 study aimed to compare
the benefit-risk profiles of lenalidomide and placebo, and evaluate
the relationship between lenalidomide exposure, including dose
reductions and duration of treatment, and clinical benefit in patients
with lower-risk, non-del(5q) MDS.
Patients and Methods
Study Design and Treatment
Full details of patient eligibility criteria and study design have
been described previously.6 Briefly, eligible patients were aged  18
years, had transfusion-dependent anemia owing to IPSS Low- or
Int-1-risk MDS, had non-del(5q) karyotype, and were ineligible for
or refractory to ESAs. Patients were considered RBC-TD if they had
an average transfusion requirement of  2 units packed RBCs
(pRBCs) per 28 days and no 8 consecutive weeks without RBC
transfusions in the 16 weeks before randomization. Patients were
considered refractory to ESAs if they were RBC-TD despite ESA
treatment ( 40,000 units/week of recombinant human EPO for 8
weeks, or equivalent dose of darbepoetin). Patients were considered
ineligible for ESAs if their serum EPO level was > 500 mU/mL
with no prior ESA exposure.
Patients were randomized 2:1 to receive either oral lenalidomide
10 mg or matching placebo once daily (both on 28-day cycles).
The starting dose of lenalidomide was 5 mg daily for patients with
creatinine clearance  40 to < 60 mL/min. Patients withClinical Lymphoma, Myeloma & Leukemia April 2019RBC-TI  8 weeks or erythroid response by week 24 continued
double-blind treatment until erythroid relapse, disease progression,
unacceptable toxicity, or consent withdrawal. The trial was regis-
tered at ClinicalTrials.gov, trial number NCT01029262.
Endpoints
The primary endpoint of the MDS-005 study was the rate of
RBC-TI for  8 consecutive weeks. Secondary endpoints included
RBC-TI  24 weeks, duration of RBC-TI, time to onset of RBC-TI,
erythroid response, HRQoL, and safety. Cytogenetic response (CyR)
was assessed in patients with baseline cytogenetic abnormalities
and  1 follow-up assessment by central review using conventional
metaphase cytogenetic analysis according to International Working
Group 2006 criteria.13 Major CyR was defined as absence of cyto-
genetic abnormalities if preexisting abnormalities were present; minor
CyR was defined as  50% reduction in abnormal metaphases. AEs
were coded using the Medical Dictionary for Regulatory Activities
(MedDRA) version 16.1 and graded according to the National
Cancer Institute Common Terminology Criteria for Adverse Events
(NCI-CTCAE) version 3.0. Lenalidomide dose modifications or
interruptions related to AEs were predefined in the study protocol.6
Cumulative dose, dose reductions, and discontinuations were recor-
ded as part of the original study.
For this analysis, the composite endpoint of clinical benefit
consisted of any of the following responses: RBC-TI  8 consec-
utive weeks; transfusion reduction of  4 units pRBCs  8
weeks13; Hb increase of  1.5 g/dL  8 weeks13; or CyR.13 The
rate of transfusion reduction  4 units pRBCs for  8 weeks was
calculated based on data collected during a 16-week period. The
timing of assessments for clinical benefit response is shown in
Supplemental Figure 1 (in the online version). Evaluation of CyR
was also conducted independently of the composite endpoint. The
data cutoff date for this analysis was March 17, 2014.
Statistical Analysis
For each treatment group, the proportion of patients achieving a
response (RBC-TI  8 weeks or clinical benefit) was assessed.
Clinical benefit was defined as the proportion of patients who
met  1 of the clinical benefit composite endpoint criteria. Patients
who met multiple criteria were only counted once. The statistical
assessment of clinical benefit assumed a binomial distribution for
the composite endpoint. For both RBC-TI  8 weeks and clinical
benefit, 95% confidence intervals (CIs) were calculated using a
generalized linear model for binomial distributed data. Risk differ-
ences were estimated using an identity link function, relative risks
were estimated using a log link function, and odds ratios (ORs) were
estimated using a logit link function.
An evaluation of cumulative lenalidomide exposure, duration of
treatment, and incidence and duration of response (RBC-TI  8
weeks and clinical benefit) was performed in relation to the inci-
dence of lenalidomide dose reductions.
At the individual patient level, cumulative mean benefit-risk ratios
were calculated for each cycle using a bivariate generalized linear
model assuming a binomial distribution with a log link function.
Benefit was defined in 2 ways: the cumulative proportion of patients
meeting the criteria for the primary endpoint of RBC-TI  8 weeks,
and the cumulative proportion of patients meeting the criteria for the
Table 1 Baseline Characteristics of Patients in the MDS-005 Study
Characteristic Lenalidomide (n [ 160) Placebo (n [ 79) Overall (N [ 239)
Median age, y (range) 71.0 (46.0-87.0) 70.0 (43.0-87.0) 71.0 (43.0-87.0)
Male, n (%) 108 (67.5) 54 (68.4) 162 (67.8)
Median time since diagnosis, y (range) 2.7 (0.1-29.6) 2.6 (0.3-20.2) 2.6 (0.1-29.6)
Median pRBC transfusion burden, units/28 d (range) 3.0 (1.8-8.8) 3.3 (1.5-9.8) 3.0 (1.5-9.8)
IPSS risk category, n (%)
Low 85 (53.1) 30 (38.0) 115 (48.1)
Intermediate-1 75 (46.9) 49 (62.0) 124 (51.9)
Prior MDS therapy, n (%) 135 (84.4) 65 (82.3) 200 (83.7)
Prior ESA treatment, n (%) 125 (78.1) 63 (79.7) 188 (78.7)
Prior G-CSF use, n (%) 27 (16.9) 11 (13.9) 38 (15.9)
Serum EPO level at screening, n (%)
 500 mU/mL 97 (60.6) 50 (63.3) 147 (61.5)
> 500 mU/mL 58 (36.3) 28 (35.4) 86 (36.0)
Missing 5 (3.1) 1 (1.3) 6 (2.5)
Ring sideroblast status,a n (%)
< 15% 52 (32.5) 19 (24.1) 71 (29.7)
 15% 108 (67.5) 60 (75.9) 168 (70.3)
Median bone marrow blast, % (range) 3.0 (0.0-9.5) 2.5 (0.0-8.0) 2.5 (0.0-9.5)
Median ANC,  109/L (range) 2.4 (0.5-12.2) 2.1 (0.3-10.6) 2.3 (0.3-12.2)
Median platelet count,  109/L (range) 243.5 (43.0-746.0) 233.0 (60.0-1063.0) 239.0 (43.0-1063.0)
Median hemoglobin, g/dL (range) 8.7 (5.5-12.3) 8.6 (5.6-11.8) 8.7 (5.5-12.3)
Abbreviations: ANC ¼ absolute neutrophil count; EPO ¼ erythropoietin; ESA ¼ erythropoiesis-stimulating agent; G-CSF ¼ granulocyte colony-stimulating factor; IPSS ¼ International Prognostic
Scoring System; MDS ¼ myelodysplastic syndromes; pRBC ¼ packed red blood cells; RARS ¼ refractory anemia with ring sideroblasts; RCMD ¼ refractory cytopenia and multilineage dysplasia.
aFor patients with RARS or RCMD.
Guillermo Garcia-Manero et alcomposite endpoint of clinical benefit. Risk was defined as the cu-
mulative proportion of patients with  1 hematologic TEAE. In the
MDS-005 study, grade 3 to 4 nonhematologic TEAEs were rare,6,12
and nonhematologic TEAEs were therefore not included in the
benefit-risk analysis. The probability of assessing a favorable benefit-
risk ratio of the lenalidomide group relative to the placebo group was
calculated by fitting the bivariate generalized linear model to the data
via generalized estimating equations at each cycle,14,15 as described in
greater detail in the Supplemental Methods (in the online version).
Adjusted mean platelet levels during cycles 1 to 4 were assessed
according to response (RBC-TI  8 weeks) using a linear mixed
model for repeated measures, as described in the Supplemental
Methods (in the online version).
Results
Baseline Patient Characteristics
From February 2010 to June 2013, 239 patients were enrolled at
72 treatment centers and randomized to lenalidomide (n ¼ 160) or
placebo (n ¼ 79). Baseline characteristics were well-balanced across
treatment groups (Table 1). At baseline, patients were receiving a
median of 3.0 units of pRBC per 28 days (range, 1.5-9.8 units),
78.7% of patients had received prior ESAs, and 36.0% had a serum
EPO level > 500 mU/mL.
Clinical Benefit  8 Weeks
Lenalidomide was associated with a higher proportion of patients
achieving the composite endpoint of clinical benefit, comparedwith placebo (31.9% vs. 3.8%) (Table 2) as well as higher pro-
portions meeting each criterion of the composite endpoint
(achievement of RBC-TI  8 weeks, reduction in transfusion
burden of  4 pRBC units  8 weeks, Hb increase of  1.5 g/dL
for  8 weeks, and CyR).
CyR
Among 43 patients evaluable for CyR, 9 (33.3%) of 27 patients
in the lenalidomide group and none (0%) of 16 patients in the
placebo group achieved CyR. Of these 9 patients, 5 (55.6%)
achieved a major response and 4 (44.4%) achieved a minor response
as best response. Five (55.6%) of the 9 responders also achieved
RBC-TI  8 weeks. All 5 patients who achieved a major CyR had
the þ8 abnormality at baseline (Table 3).
Lenalidomide Dose Reduction and Treatment
Discontinuation
Of the 160 patients treated with lenalidomide, 77 (48.1%)
underwent  1 dose reduction. The median time to first dose
reduction was 85 days (interquartile range [IQR], 50-114). Baseline
characteristics were comparable between patients with or without
dose reductions (see Supplemental Table 1 in the online version).
Most dose reductions were implemented in response to TEAEs: 102
dose reductions in 73 (45.6%) patients were attributed to TEAEs.
Of these TEAE-related dose reductions, 47 (46.1%) were due to
neutropenia, 33 (32.4%) to thrombocytopenia, and 2 (2.0%) to
other hematologic conditions. Nonhematologic TEAEs leading toClinical Lymphoma, Myeloma & Leukemia April 2019 - 215










Clinical benefit 51 (31.9) 3 (3.8) 11.85 (3.57-39.38) 8.39 (2.70-26.06)
RBC-TI  8 weeks 43 (26.9) 2 (2.5) 14.15 (3.33-60.12) 10.62 (2.64-42.70)
Transfusion reduction  4 pRBC units  8 weeksa 34 (21.3) 0 N/Ab N/Ab
Hb increase  1.5 g/dL  8 weeks 31 (19.4) 2 (2.5) 9.25 (2.15-39.74) 7.65 (1.88-31.17)
CyR 9 (5.6) 0 N/Ab N/Ab
Abbreviations: CI ¼ confidence interval; CyR ¼ cytogenetic response; Hb ¼ hemoglobin; N/A ¼ not applicable; pRBC ¼ packed red blood cells; RBC-TI ¼ red blood cell transfusion independence.
aData normalized to 8 weeks using data from a 16-week assessment period divided by 2.
bOdds ratio and relative risk cannot be reliably estimated due to 0 events in the placebo group.
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216 -dose reductions included 3 (2.9%) occurrences of asthenia and 3
(2.9%) occurrences of rash.
TEAEs led to discontinuation of lenalidomide in 51 (31.9%)
patients; 23 (14.4%) of these patients discontinued before the end
of cycle 3. The most common AEs leading to discontinuation,
occurring in  1.5% of patients, were thrombocytopenia (8.8%),
neutropenia (4.4%), and deep vein thrombosis (1.9%).
Lenalidomide Dose Adjustments and Treatment Exposure
Of the 77 patients who had  1 dose reduction, 6 (7.8%) had a
dose reduction in the first cycle and 37 (48.1%) had dose reductions
during cycles 1 to 3 (Table 4). During the first 3 cycles, patients
with  1 dose reduction received a lower median dose than those
with no dose reduction (385 mg [IQR, 318-520 mg] vs. 660 mg
[IQR, 415-840 mg]). However, when analyzed over the course of
the study, patients with  1 dose reduction received a higher me-
dian cumulative dose than those with no dose reductions (950 mg
[IQR, 595-1435 mg] vs. 715 mg [IQR, 370-1660 mg]). Similarly,
duration of treatment was longer for patients with  1 dose
reduction compared with those with no dose reductions (172 days
[IQR, 140-391 days] vs. 92 days [IQR, 46-168 days]).
Lenalidomide Exposure and Response
The relationship between lenalidomide dose reductions and
achievement of either RBC-TI  8 weeks or clinical benefit is
shown in Table 5. Patients with  1 dose reduction were more





1 Major 47, XX, þ8
2 Major 47, XY, þ8
3 Major 47, XY, þ8
4 Major 47, XY, þ8a
5 Major 47, XY, þ8
6 Minor 47, XX, þ8
7 Minor 47, XX, þ8
8 Minor 46, XX, del(12q)
9 Minor 45, X, Y
aBaseline karyotype data for first collection are not available; assessment of the second
collection is reported instead.
Clinical Lymphoma, Myeloma & Leukemia April 2019reductions (39% vs. 16%; OR, 3.44; 95% CI, 1.63-7.26). Among
patients who achieved RBC-TI  8 weeks, the median duration of
response was longer in patients who underwent  1 dose reduction
than in those who did not (29.6 weeks [range, 8.1-123.7 weeks] vs.
23.7 weeks [range, 9.9-103.7 weeks]). Similarly, patients with  1
dose reduction were also more likely to achieve clinical benefit  8
weeks (47% vs. 18%; OR, 3.98; 95% CI, 1.94-8.15).
Clinical Benefit-Risk Ratio
The benefit-risk ratio per cycle for each treatment group is shown
in Figure 1. For cycles 1 to 7, the benefit-risk ratio, in terms of the
proportion of patients achieving RBC-TI  8 weeks relative to the
risk of hematologic TEAEs, favored lenalidomide treatment over
placebo (Figure 1A). The probability that the RBC-TI  8 weeks-
risk ratio was relatively greater for lenalidomide than for placebo was
0.83 in cycle 1; this probability increased to 0.90 by cycle 4.
Similarly, the ratio of clinical benefit-risk favored the lenalidomide
arm over the placebo arm (Figure 1B). In cycle 1, the probability
that the clinical benefit-risk ratio was relatively greater for lenali-
domide than for placebo was 0.91, and remained fairly consistent
throughout the other cycles evaluated.
Relationship Between Hematologic Toxicity and Response
A decrease in mean platelet levels (after adjusting for baseline
values as a covariate) did not predict achievement of RBC-TI  8
weeks in the MDS-005 study population (Figure 2). An exploratory
analysis in patients with or without isolated anemia also showed no
relationship between platelet level and achievement of RBC-TI  8Table 4 Lenalidomide Exposure in Patients With or Without
Reductions
Characteristic ‡ 1 Dose Reduction No Dose Reduction
Cumulative dose in
cycle 1, mg
n ¼ 6 n ¼ 154
Median (IQR) 145 (77.5-160.0) 280 (150.0-280.0)
Cumulative dose in
cycles 1-3, mg
n ¼ 37 n ¼ 123
Median (IQR) 385 (317.5-520.0) 660 (415.0-840.0)
Total cumulative dose, mg n ¼ 77 n ¼ 83
Median (IQR) 950 (595.0-1435.0) 715 (370.0-1660.0)
Duration of treatment, d n ¼ 77 n ¼ 83
Median (IQR) 172.0 (140.0-391.0) 92.0 (46.0-168.0)
Abbreviation: IQR ¼ interquartile range.
Table 5 Response to Lenalidomide by Incidence of Dose Reductions
Response, n/N (%)
‡ 1 Dose Reduction
(n [ 77)
No Dose







RBC-TI  8 w 30/77 (39) 13/83 (16) 23 (10-37) 3.44 (1.63-7.26) 2.49 (1.40-4.41)
Clinical benefit 36/77 (47) 15/83 (18) 29 (15-43) 3.98 (1.94-8.15) 2.59 (1.54-4.34)
Abbreviations: CI ¼ confidence interval; RBC-TI ¼ red blood cell transfusion independence.
Guillermo Garcia-Manero et alweeks (see Supplemental Figure 2 in the online version). In
lenalidomide-treated patients with isolated anemia, rates of
RBC-TI  8 weeks (26.8%) and clinical benefit (30.9%) were
consistent with the overall population (26.9% and 31.9%,
respectively) (Table 2).
Discussion
In this analysis of RBC-TD patients with lower-risk non-del(5q)
MDS ineligible for or refractory to ESAs, lenalidomide was associ-
ated with significantly greater clinical benefit compared with
placebo. This newly defined composite endpoint of clinical benefit
comprised the clinically meaningful endpoints of reduced trans-
fusion burden, increased Hb, and CyR in addition to achievement
of RBC-TI. Both RBC-TI and Hb level have been shown to be
important predictors of HRQoL in MDS.8,16,17 At the individual
patient level, some patients may respond by one clinical definition
but not by another; it is therefore important to consider these other
indicators of therapeutic benefit when making treatment decisions.
We found that patients who underwent  1 lenalidomide dose
reduction were more likely to achieve RBC-TI and clinical benefit
than patients with no dose reductions. This apparent disparity can
be explained by the finding that patients undergoing  1 dose
reduction also had a longer duration of treatment, leading to a
higher cumulative treatment exposure. Employing lenalidomide
dose reductions instead of treatment discontinuation in response to
AEs may allow patients to remain on treatment longer, leading toFigure 1 Ratio of RBC-TI ‡ 8 Weeks Benefit-Risk (A) and Clinical B
Abbreviations: AE ¼ adverse event; LEN ¼ lenalidomide; PBO ¼ placebo; RBC-TI ¼ red blood cell tra
the benefit-risk ratio is higher for patients treated with LEN compared with PBO.increased drug exposure and better outcomes. In MDS-005, the
median time to onset of response was 10.1 weeks6; therefore, pa-
tients who discontinued treatment within the first 3 cycles may not
have received a sufficient duration of therapy to achieve a response.
Previous findings in patients with del(5q) MDS support this
finding: in the MDS-003 and MDS-004 studies, lenalidomide dose
reductions were associated with improved leukemia-free survival and
overall survival outcomes.18
Maintaining the highest tolerated dose may also be important to
patient outcomes. In a pooled analysis of data from phase II and III
studies of lenalidomide in patients with del(5q) MDS, receipt of a
higher dose in cycle 1 was associated with improved short- and long-
term responses.18,19 In the non-del(5q) population of the MDS-005
study, a preliminary analysis showed that more patients who
received a higher cumulative lenalidomide dose in cycle 1 (> 210
mg) achieved RBC-TI  8 weeks (36/105 [34.3%]) and clinical
benefit (42/105 [40.0%]), compared with patients receiving  210
mg (7/55 [12.7%] and 9/55 [16.4%], respectively). It should,
however, be noted that the lenalidomide starting dose in MDS-005
was adjusted based on each patient’s creatinine clearance, which
could have introduced a bias in the relationship between cumulative
dose and response.
The most common reasons for lenalidomide dose adjustments
were neutropenia and thrombocytopenia. This finding is consistent
with data from a phase II trial evaluating lenalidomide with or
without EPO in RBC-TD patients with lower-risk non-del(5q)enefit-Risk (B) per Cycle in Patients Receiving LEN or PBO
nsfusion independence. aProbability (LEN > PBO) was calculated based on the assumption that
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Figure 2 Adjusted Mean (95% Confidence Interval) Platelet
Levels Among Responders and Non-Responders by
Lenalidomide Treatment Cycle
Abbreviation: RBC-TI ¼ red blood cell transfusion independence.
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218 -MDS refractory to ESAs, in which cytopenias were the most
common reason for dose reduction.20 Rates of discontinuation
owing to neutropenia or thrombocytopenia were low in the MDS-
005 trial, suggesting that these events can be effectively managed
with dose reduction or treatment interruption. In this population of
lower-risk patients, cytopenias were more likely to develop as a
TEAE than as a result of disease progression, allowing for man-
agement through dose modification.
The benefit-risk ratio in patients treated with lenalidomide was
consistently higher than in patients receiving placebo. This suggests
that, compared with placebo, the positive effects of lenalidomide
treatment may outweigh the negative effects associated with an
increased risk of hematologic TEAEs. In both treatment groups, the
benefit-risk ratio remained below 1 due to a higher incidence of
hematologic TEAEs reported, relative to the incidence of clinical
benefit observed.
In our analysis, myelosuppression did not predict response to
lenalidomide. Similar results were obtained in a retrospective
analysis of data from 2 phase II studies of lenalidomide, in which a
reduction in platelet or neutrophil count was associated with
achievement of RBC-TI in patients with del(5q), but not in those
without del(5q).21 Thus, lenalidomide-related cytopenias may act
as a surrogate marker of clonal suppression in patients with del(5q)
MDS, but cytopenias do not appear to predict response in patients
with non-del(5q) MDS. It should be noted that patients were
excluded from the MDS-005 trial if they had thrombocytopenia
(ie, platelet count < 50  109/L) or neutropenia (ie, absolute
neutrophil count < 0.5  109/L) at baseline. This may have
influenced the lack of correlation between cytopenias and
response. A preliminary analysis of response according to baseline
platelet count showed that patients with low platelet counts
(50-100  109/L) were less likely to achieve RBC-TI  8 weeks
(2/15 [13.3%]) than patients with platelet counts of > 100  109/
L (41/144 [28.5%]).
This analysis is limited by its retrospective nature. Also, it should
be noted that the lenalidomide starting dose was adjusted based on
creatinine clearance, which could have influenced the relationship
between cumulative dose and response. As patients with moderateClinical Lymphoma, Myeloma & Leukemia April 2019renal impairment received a lower starting dose, the impact of the
starting dose on other outcomes could not be assessed.
Conclusion
In summary, lenalidomide treatment was associated with a higher
rate of clinical benefit than placebo in patients with non-del(5q)
lower-risk MDS who were refractory to or ineligible for ESAs.
Although treatment with lenalidomide was associated with an
increased incidence of hematologic AEs, the overall benefit-risk ratio
of lenalidomide treatment was more favorable than that of placebo.
Managing hematologic AEs with appropriate dose reductions can
help patients remain on treatment longer, thereby increasing the
chance of achieving clinical benefit.
Clinical Practice Points
 Achievement of RBC-TI is a particularly meaningful endpoint
for patients with RBC-TD anemia because prolonged RBC
transfusion dependence is associated with significant clinical and
HRQoL consequences.
 Our analysis supports the clinical benefit of lenalidomide in
RBC-TD patients with non-del(5q) lower-risk MDS: a higher
proportion of patients treated with lenalidomide achieved the
composite endpoint of clinical benefit compared with placebo.
This newly defined composite endpoint comprised the clinically
meaningful endpoints of achievement of RBC-TI, reduced
transfusion burden, increased Hb, and CyR. These data provide
evidence that other measures of response in addition to RBC-TI
may be valuable in the management of patients with non-del(5q)
lower-risk MDS.
 Despite the occurrence of hematologic AEs, the benefit-risk
profile consistently favored lenalidomide over placebo. This
suggests that the positive effects of lenalidomide treatment may
outweigh the negative effects associated with an increased risk of
hematologic TEAEs.
 Patients undergoing lenalidomide dose reductions had a longer
duration of treatment and were more likely to experience clinical
benefit compared with patients without dose reductions. This
finding suggests that lenalidomide dose reductions may allow
patients who experience AEs to remain on treatment longer,
leading to increased drug exposure and better outcomes.
 Overall, these data support the use of lenalidomide in patients
with non-del(5q) lower-risk MDS who are ineligible for or re-
fractory to ESAs.Acknowledgments
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Supplemental Methods
Modeling and Calculation of Benefit-Risk Ratios
The bivariate generalized linear model has 2 assessment aspects to
it, one which assesses benefit whereas the other assesses risk. Both
benefit and risk can be modeled separately as described below:
(1) Let Y ð1Þi be the response for benefit, which takes on the
value 1 if the benefit criterion is met for a given subject and
0 otherwise.












Linear predictor : hð1Þi ¼ mð1Þ þ sð1Þi ;bT ¼ " bsi¼1 þ bqj¼1 þcsqi¼1;j¼1! bsi¼1 þ bqj¼2 þcsqi¼1;j¼2!# " bsi¼2 þ bqj¼1 þcsqi¼2;j¼1! bsi¼2 þ bqj¼2 þcsqi¼2;j¼2!#where pð1Þi is the parameter for the proportion of benefit
responders for the ith treatment group (i ¼ 1 for lenalidomide
[LEN] and i ¼ 2 for placebo [PBO]), ni is the sample size for
the ith treatment group, and hð1Þi is the linear predictor for
modeling the proportion of benefit responders on the log scale.
The modeling terms we are interested in estimating involve the
intercept, mð1Þ, and the treatment effect, sð1Þi .
2) Let Y ð2Þi be the response for risk, which takes on the value 1
if a hematologic treatment-emergent adverse event (TEAE)
occurs for a given subject and 0 otherwise.












Linear predictor : hð2Þi ¼ mð2Þ þ sð2Þi ;
where pð2Þi is the parameter for the proportion of hematological
TEAEs for the ith treatment group (i ¼ 1 for LEN and i ¼ 2 for
PBO), and all other terms follow the same sort of interpretation
as described for the previous model, but as applied to assessing
the risk.
As we are interested in modeling benefit-risk simultaneously, we
can introduce an additional modeling term that we will name qj
(j ¼ 1 for the benefit-response type, j ¼ 2 for the risk-response type).1 - Clinical Lymphoma, Myeloma & Leukemia April 2019Furthermore, because we are also interested in comparing the treat-
ment groups with respect to benefit-risk, an interaction term is also
required, namely sqij . Assuming a binomial distribution and log link
as previously, this leads us to the following linear predictor:
Linear predictor : hij ¼ mþ si þ qj þ sqij :
Note that by introducing the response type term, qj , we can drop
the superscripts (1) and (2) and replace it with subscript j to allow
for the inclusion of response type.
Because we are modeling the benefit and risk simultaneously on
the same set of subjects, recall that there is a shared ni for Y
ð1Þ
i and
Y ð2Þi , so a correlation structure must be accounted for in estimating
the terms in the model and their respective variances. Hence, we
used generalized estimating equations with a compound symmetry
structure as our working correlation in obtaining all our
estimates.1,2
To make a comparison of benefit-risk between the treatment
groups, the following estimator can be constructed using the terms
from the linear predictor:where bT w N ðmT ; s2T Þ.
The terms contained within the first squared bracket, namelybT LEN ¼ ½ðbsi ¼ 1 þ bqj ¼ 1 þ csqi ¼ 1;j ¼ 1Þ ðbsi ¼ 1 þ bqj ¼ 2 þcsqi ¼ 1;j ¼ 2Þ, is the benefit-risk associated with the LEN group.
When exponentiating bT LEN , the benefit-risk estimates will be on the
ratio scale (ie, benefit:risk) as a log link function was used in the model.
The terms contained within the second squared bracket, namelybT PBO ¼ ½ðbsi ¼ 2 þ bqj ¼ 1 þ csqi ¼ 2;j ¼ 1Þ ðbsi ¼ 2 þ bqj ¼ 2 þcsqi ¼ 2;j ¼ 2Þ, is the benefit-risk associated with the PBO group.
Likewise, when exponentiating bT PBO , the benefit-risk estimates will
be on the ratio scale.
To obtain the relevant probabilities that the benefit-risk data
from this study supports the hypothesis that the LEN group has a
greater benefit-risk than the PBO group in terms of the unknown
mean parameter mT [ie, PrðbT > 0Þ], we simply apply the model to
the observed data to obtain the estimates for the mean ðestmT Þ and
standard error ð ffiffiffiffiffiffiffiffiffiests2Tp Þ:






p ;where FðÞ is the cumulative normal density function,
is calculated.
The model and the calculation of the probabilities described
above were performed for each treatment cycle where cumulative
events for both benefit and risk were incorporated in our
assessments.
Note that using the maximum likelihood estimates of the
benefit-risk ratios of LEN relative to PBO to construct a
Guillermo Garcia-Manero et alprobability statement under an assumed asymptotic distribution is
analogous to using a posterior distribution of a relative difference
of the benefit-risk ratios between the 2 treatment groups with a
non-informative prior.
Because the estimated within-subject correlation between the
benefit endpoints and the risk endpoint was estimated to be very
small, a beta-binomial model with a beta (1/3, 1/3) non-
informative prior3 was used as a sensitivity analysis assuming
independence (ie, zero within subject correlation) between the
benefit endpoints and the risk endpoint. The results from using
the beta-binomial model to establish a formal posterior distri-
bution were consistent with our bivariate modeling approach,
although it yielded slightly more favorable probabilities for LEN
than the bivariate modeling approach.
The generalized linear model procedure (PROC GENMOD) in
SAS, Version 9.1 (SAS Institute Inc, Cary, NC) was used for these
analyses.Analysis of Platelet Levels According to Response
Adjusted mean platelet levels during cycles 1 to 4 were assessed
according to response (red blood cell transfusion independence
[RBC-TI]  8 weeks) using a linear mixed model for repeated
measures. Prior to modeling, a log transformation was applied to both
post-treatment platelet responses and baseline platelet values. The
linear mixed model contained a cell means parameterization for RBC-
TI (responder vs. non-responder) and cycle as fixed effects, and an
unstructured within-subject covariance. Ninety-five percent confi-
dence intervals (95% CI) for the adjusted means were constructed as
the least squares means 2 standard errors. An additional exploratory
analysis of patients with isolated anemia and non-isolated anemia was
also conducted. For this analysis, the same approach was taken with
respect to employing a linear mixed model for repeated measures, but
with a cell means parameterization for RBC-TI, isolated anemia (yes
vs. no), and cycle. The mixed procedure (PROC MIXED) in SAS,
Version 9.1 was used for these analyses (SAS Institute Inc).Clinical Lymphoma, Myeloma & Leukemia April 2019 - 219.e2
Supplemental Figure 2 Adjusted Mean (95% Confidence Interval) Platelet Levels Among Responders and Non-Responders With
Isolated Anemia and Non-isolated Anemia by Lenalidomide Treatment Cycle
Abbreviation: RBC-TI ¼ red blood cell transfusion independence.
Supplemental Figure 1 Timing of Clinical Benefit Response Measurements in Patients in the MDS-005 Study
Abbreviations: DB ¼ double-blinded; LEN ¼ lenalidomide; PBO ¼ placebo; RBC-TI ¼ red blood cell transfusion independence.
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Supplemental Table 1 Baseline Characteristics of Lenalidomide-treated Patients With or Without Dose Reductions
Characteristic ‡ 1 Dose Reduction (n [ 77) No Dose Reduction (n [ 83)
Median age, y (range) 70 (50-85) 71 (46-87)
Male, n (%) 52 (67.5) 56 (67.5)
Median time since diagnosis, y (range) 3.3 (0.2-29.6) 2.5 (0.1-23.9)
IPSS risk, n (%)
Low 37 (48.1) 48 (57.8)
Int-1 40 (51.9) 35 (42.2)
Median RBC transfusion burden, units (range) 3.0 (1.8-8.8) 3.0 (1.8-6.8)
Prior MDS therapy, n (%)
No 10 (13.0) 15 (18.1)
Yes 67 (87.0) 68 (81.9)
Prior ESA therapy, n (%)
No 13 (16.9) 22 (26.5)
Yes 64 (83.1) 61 (73.5)
Median bone marrow blast, % (range) 3.0 (0-9.5) 3.0 (0-8.5)
Median ANC,  109/L (range) 2.4 (0.5-12.2) 2.4 (0.5-7.7)
Median platelet count,  109/L (range) 224 (43-588) 263 (51-746)
Median Hb, g/dL (range) 8.6 (5.8-12.3) 8.7 (5.5-11.3)
Abbreviations: ANC ¼ absolute neutrophil count; ESA ¼ erythropoiesis-stimulating agent; Hb ¼ hemoglobin; Int ¼ Intermediate; IPSS ¼ International Prognostic Scoring System; MDS ¼ mye-
lodysplastic syndrome; RBC ¼ red blood cell.
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